Michael Barbella, Managing Editor04.08.24
The healthcare community has added another tool to its COVID-19 weapons arsenal.
electroCore Inc. has been granted a U.S. patent related to systems and methods for treating Coronaviridae family (COVID) viruses.
U.S. Patent No. 11,894,148—“Systems and Methods for Treating Patients With Diseases Associated With Viruses”—generally covers methods for treating disorders from COVID-related viruses. The specified treatment uses electrical impulses transmitted transcutaneously to the vagus nerve for about 30 seconds to five minutes, between two to five times daily to reduce a level of C-reactive protein in a patient's blood. Stimulating the vagus nerve affects many important autonomic functions in the brain and body, including neurotransmitter levels, inflammation levels, and metabolism.
Founded in 2005, electroCore Inc. is a commercial stage bioelectronic medicine and wellness company developing non-invasive vagus nerve stimulation (nVNS) technology. It aims to commercialize medical devices for managing and treating certain medical conditions and consumer product offerings using nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
electroCore Inc. has been granted a U.S. patent related to systems and methods for treating Coronaviridae family (COVID) viruses.
U.S. Patent No. 11,894,148—“Systems and Methods for Treating Patients With Diseases Associated With Viruses”—generally covers methods for treating disorders from COVID-related viruses. The specified treatment uses electrical impulses transmitted transcutaneously to the vagus nerve for about 30 seconds to five minutes, between two to five times daily to reduce a level of C-reactive protein in a patient's blood. Stimulating the vagus nerve affects many important autonomic functions in the brain and body, including neurotransmitter levels, inflammation levels, and metabolism.
Founded in 2005, electroCore Inc. is a commercial stage bioelectronic medicine and wellness company developing non-invasive vagus nerve stimulation (nVNS) technology. It aims to commercialize medical devices for managing and treating certain medical conditions and consumer product offerings using nVNS to promote general wellbeing and human performance in the United States and select overseas markets.